Atezolizumab plus Bevacizumab — A Landmark in Liver Cancer

More than a decade ago, sorafenib became the first systemic therapy that conferred a meaningful survival benefit in the treatment of advanced hepatocellular carcinoma.1 Since then, no treatment had surpassed the effect of sorafenib in the first line until the regimen of atezolizumab and bevacizumab now reported by Finn and colleagues in this issue of the Journal.2 Treatment with the combination of atezolizumab, a programmed death ligand 1 (PD-L1) inhibitor, and bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, resulted in significantly longer overall and progression-free survival as well as strikingly better patient-reported outcomes than sorafenib. These data . . .